Clinical Trials in Lemon Grove, California
13 recruiting
Showing 1–13 of 13 trials
Recruiting
Phase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Major Depressive Disorder
AbbVie195 enrolled31 locationsNCT07276997
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics280 enrolled175 locationsNCT05304767
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Major Depressive Disorder (MDD)
Vanda Pharmaceuticals500 enrolled38 locationsNCT06830044
Recruiting
Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
Alzheimer Disease
Alzheimer's Disease Cooperative Study (ADCS)406 enrolled47 locationsNCT06223360
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled60 locationsNCT06894212
Recruiting
Phase 3
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Weight Loss
Viking Therapeutics, Inc.1,100 enrolled134 locationsNCT07104383
Recruiting
Phase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD)
AbbVie315 enrolled52 locationsNCT06846320
Recruiting
Phase 3
Randomized Withdrawal Study in Patients With Schizophrenia
Schizophrenia
Vanda Pharmaceuticals400 enrolled22 locationsNCT06961968
Recruiting
Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.705 enrolled69 locationsNCT06480383
Recruiting
Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Sirtsei Pharmaceuticals, Inc.456 enrolled50 locationsNCT06254612
Recruiting
Phase 2
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.150 enrolled13 locationsNCT07191483
Recruiting
Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Schizophrenia
Reviva Pharmaceuticals690 enrolled18 locationsNCT05184335